✦ LIBER ✦

Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients

✍ Scribed by Warren K. Bickel; Leslie Amass; John P. Crean; Gary J. Badger

Book ID: 105885069
Publisher: Springer
Year: 1999
Tongue: English
Weight: 76 KB
Volume: 146
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s002130051096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacodynamics of diazepam co-administ

Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients

✍ Nicholas Lintzeris; Timothy B. Mitchell; Alyson J. Bond; Liam Nestor; John Stran 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 832 KB

A phase I study of bendamustine hydrochl

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

✍ Rasschaert, M; Schrijvers, D; Van den Brande, J; Dyck, J; Bosmans, J; Merkle, K; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

A phase 1 study of OSI-211 given as an i

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

✍ K. Gelmon; H. Hirte; B. Fisher; W. Walsh; M. Ptaszynski; M. Hamilton; N. Onetto; 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 283 KB

Albinterferon alfa-2b dosed every two or

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

✍ Stefan Zeuzem; Eric M. Yoshida; Yves Benhamou; Stephen Pianko; Vincent G. Bain; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 528 KB

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a phase 2b, open-label study of patients with genotype 1, chronic hepatitis C. In all, 458 IFN-alfa treatment-naı ¨ve patients

516 A phase 1 dose-escalation study to e

516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

✍ G. Weiss; R. Donehower; E. Westin; A. Bence; S. Hynes; K. Hurt 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase I and pharmacokinetic study of Yon

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

✍ C. Twelves; K. Hoekman; A. Bowman; J.B. Vermorken; A. Anthoney; J. Smyth; C. van 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 279 KB